AMA CPT® Assistant - 2025 Issue 3 (March)
Reporting Amyloid Protein Codes (82233, 82234) (March 2025)
March 2025 page 11 Reporting Amyloid Protein Codes (82233, 82234) For the CPT 2025 code set, two new Category I codes (82233, 82234) were established to report testing for amyloid beta 1-40 (Abeta 40) and 1-42 (Abeta 42). This article provides an overview of the intent and appropriate reporting of these new codes. Chemistry 82233Beta-amyloid; 1-40 (Abeta 40) 822341-42 (Abeta 42) Codes 82233 and 82234 were established to describe tests for the detection of Abeta-40 and Abeta-42 proteins, both of which are the direct results of the enzymatic cleavage of the amyloid precursor protein. Abeta 40 is the most...
Subscribe or sign in to view the full article.
Article Overview
This CPT 2025 article describes the addition of two new laboratory codes for amyloid beta protein testing and explains the general reporting context for these assays. It is aimed at coding professionals and laboratory staff who need to understand the scope, intent, and typical clinical scenarios associated with the new services.
Why This Topic Matters
It helps readers recognize a 2025 CPT update affecting amyloid-related laboratory reporting and understand the broader clinical and coding context for these tests.
Article Sections
-
Overview
Introduces the CPT 2025 update and the purpose of the article. Summarizes the general testing area and reporting focus.
-
Chemistry
Lists the new laboratory services discussed in the article and places them within the chemistry section. Provides the basic code-level context for the assays.
-
Clinical Example (82233) / Description of Procedure (82233)
Presents a representative patient scenario and associated procedural summary for one of the new tests. The section illustrates typical clinical context without providing detailed coding guidance.
-
Clinical Example (82234) / Description of Procedure (82234)
Presents a representative patient scenario and associated procedural summary for the other new test. The section illustrates typical clinical context without providing detailed coding guidance.
What You Will Learn
- The CPT 2025 context for new amyloid protein laboratory reporting
- The general clinical setting in which these assays are used
- How the article frames typical scenarios for the newly introduced services
- The broader diagnostic area associated with amyloid beta testing
Who Should Read This
- Medical coders
- Laboratory billing staff
- Compliance professionals
- Clinical laboratory personnel
- Health information management professionals
Codes Discussed
Subscribe or sign in to view the full article.


Quick, Current, Complete - www.findacode.com